JP2012515557A - ヒトパピローマウイルスの改良型ワクチンおよびその使用方法 - Google Patents
ヒトパピローマウイルスの改良型ワクチンおよびその使用方法 Download PDFInfo
- Publication number
- JP2012515557A JP2012515557A JP2011548155A JP2011548155A JP2012515557A JP 2012515557 A JP2012515557 A JP 2012515557A JP 2011548155 A JP2011548155 A JP 2011548155A JP 2011548155 A JP2011548155 A JP 2011548155A JP 2012515557 A JP2012515557 A JP 2012515557A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- homology
- nucleic acid
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Vehicle Cleaning, Maintenance, Repair, Refitting, And Outriggers (AREA)
Abstract
【選択図】図1
Description
Claims (40)
- 以下からなる群から選択されるヌクレオチド配列を含む核酸分子:
配列番号1;
配列番号1の断片;
配列番号1と少なくとも90%の相同性を有する配列;
配列番号1と少なくとも90%の相同性を有する配列の断片;
配列番号5;
HPVコード配列を含む配列番号5の断片;
配列番号5と少なくとも90%の相同性を有する配列;および
HPVコード配列を含む配列番号5と少なくとも90%の相同性を有する配列の断片。 - 配列番号1を含む、請求項1に記載の核酸分子。
- 配列番号1と少なくとも95%の相同性を有する配列を含む、請求項1に記載の核酸分子。
- 配列番号1と少なくとも98%の相同性を有する配列を含む、請求項1に記載の核酸分子。
- 配列番号1からなる群から選択されるヌクレオチド配列と少なくとも99%の相同性を有する配列を含む、請求項1に記載の核酸分子。
- 配列番号5を含む、請求項1に記載の核酸分子。
- 配列番号5と少なくとも95%の相同性を有する配列を含む、請求項1に記載の核酸分子。
- 配列番号5と少なくとも98%の相同性を有する配列を含む、請求項1に記載の核酸分子。
- 配列番号5からなる群から選択されるヌクレオチド配列と少なくとも99%の相同性を有する配列を含む、請求項1に記載の核酸分子。
- 以下からなる群から選択されるヌクレオチド配列を含む核酸分子:
配列番号2をコードするヌクレオチド配列;
配列番号2と少なくとも90%の相同性を有するアミノ酸配列をコードするヌクレオチド配列;
配列番号2をコードするヌクレオチド配列の断片;
配列番号2と少なくとも90%の相同性を有するアミノ酸配列をコードするヌクレオチド配列の断片;
配列番号6をコードするヌクレオチド配列;
配列番号6と少なくとも90%の相同性を有するアミノ酸配列をコードするヌクレオチド配列;
HPV配列を含む配列番号6をコードするヌクレオチド配列の断片;および
HPV配列を含む配列番号6と少なくとも90%の相同性を有するアミノ酸配列をコードするヌクレオチド配列の断片。 - 配列番号2をコードするヌクレオチド配列を含む、請求項10に記載の核酸分子。
- 配列番号6をコードするヌクレオチド配列を含む、請求項10に記載の核酸分子。
- 前記分子がプラスミドである、請求項1に記載の核酸分子。
- 請求項1に記載の核酸分子を含む医薬組成物。
- 請求項1に記載の核酸分子を含む注射可能な医薬組成物。
- HPVに対する免疫反応を個体において誘導する方法であって、請求項1に記載の核酸分子を含む組成物を、前記個体に投与するステップを含む方法。
- 前記核酸分子がDNA分子である、請求項16に記載の方法。
- 前記核酸分子がプラスミドである、請求項17に記載の方法。
- 前記核酸分子が電気穿孔法により前記個体に導入される、請求項16に記載の方法。
- 請求項1に記載の核酸分子を含む組み換えワクチン。
- 前記組み換えワクチンが組み換えワクシニアワクチンである、請求項20に記載の組み換えワクチン。
- 請求項1に記載の核酸分子を含む弱毒化生ワクチン。
- 以下からなる群から選択されるアミノ酸配列を含むタンパク質:
配列番号2;
配列番号2と少なくとも90%の相同性を有する配列;
配列番号2の断片;
配列番号2と少なくとも90%の相同性を有する配列の断片;
配列番号6;
配列番号6と少なくとも90%の相同性を有する配列;
HPV配列を含む配列番号6の断片;および
HPV配列を含む配列番号6と少なくとも90%の相同性を有する配列の断片。 - 配列番号2を含む、請求項23に記載のタンパク質。
- 配列番号2と少なくとも95%の相同性を有する配列を含む、請求項23に記載のタンパク質。
- 配列番号2と少なくとも98%の相同性を有する配列を含む、請求項23に記載のタンパク質。
- 配列番号2と少なくとも99%の相同性を有する配列を含む、請求項23に記載のタンパク質。
- 配列番号6を含む、請求項23に記載のタンパク質。
- 配列番号6と少なくとも95%の相同性を有する配列を含む、請求項23に記載のタンパク質。
- 配列番号6と少なくとも98%の相同性を有する配列を含む、請求項23に記載のタンパク質。
- 配列番号6と少なくとも99%の相同性を有する配列を含む、請求項23に記載のタンパク質。
- 請求項23に記載のタンパク質を含む医薬組成物。
- 請求項23に記載のタンパク質を含む注射可能な医薬組成物。
- 請求項23に記載のタンパク質を含む組み換えワクチン。
- 前記組み換えワクチンが組み換えワクシニアワクチンである、請求項34に記載の組み換えワクチン。
- 請求項23に記載のタンパク質を含む弱毒化生ワクチン。
- HPVに対する免疫反応を個体において誘導する方法であって、請求項23に記載のタンパク質を含む組成物を前記個体に投与するステップを含む方法。
- HPVに対する免疫反応を個体において誘導する方法であって、請求項20に記載の組み換えワクチンを前記個体に投与するステップを含む方法。
- HPVに対する免疫反応を個体において誘導する方法であって、請求項22に記載の弱毒化生ワクチンを前記個体に投与するステップを含む方法。
- 前記個体がHPV感染を有すると診断された、請求項16に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14694209P | 2009-01-23 | 2009-01-23 | |
US61/146,942 | 2009-01-23 | ||
US12/691,588 US8389706B2 (en) | 2009-01-23 | 2010-01-21 | Vaccines for human papilloma virus and methods for using the same |
US12/691,588 | 2010-01-21 | ||
PCT/US2010/021869 WO2010085697A1 (en) | 2009-01-23 | 2010-01-22 | Improved vaccines for human papilloma virus and methods for using the same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015151495A Division JP2015192673A (ja) | 2009-01-23 | 2015-07-31 | ヒトパピローマウイルスの改良型ワクチンおよびその使用方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012515557A true JP2012515557A (ja) | 2012-07-12 |
JP2012515557A5 JP2012515557A5 (ja) | 2013-03-14 |
JP5996191B2 JP5996191B2 (ja) | 2016-09-21 |
Family
ID=42352560
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011548155A Active JP5996191B2 (ja) | 2009-01-23 | 2010-01-22 | ヒトパピローマウイルスの改良型ワクチンおよびその使用方法 |
JP2015151495A Withdrawn JP2015192673A (ja) | 2009-01-23 | 2015-07-31 | ヒトパピローマウイルスの改良型ワクチンおよびその使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015151495A Withdrawn JP2015192673A (ja) | 2009-01-23 | 2015-07-31 | ヒトパピローマウイルスの改良型ワクチンおよびその使用方法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US8389706B2 (ja) |
EP (1) | EP2393496B1 (ja) |
JP (2) | JP5996191B2 (ja) |
KR (1) | KR101652764B1 (ja) |
CN (2) | CN102292089A (ja) |
AU (1) | AU2010206611B2 (ja) |
CA (2) | CA2653478A1 (ja) |
EA (1) | EA023892B1 (ja) |
ES (1) | ES2592204T3 (ja) |
HK (1) | HK1245334A1 (ja) |
MX (1) | MX2011007692A (ja) |
PL (1) | PL2393496T3 (ja) |
PT (1) | PT2393496T (ja) |
WO (1) | WO2010085697A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9050287B2 (en) | 2009-01-23 | 2015-06-09 | The Trustees Of The University Of Pennsylvania | Vaccines for human papilloma virus and methods for using the same |
US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
WO2013055326A2 (en) * | 2011-10-12 | 2013-04-18 | The Trustees Of The University Of Pennsylvania | Vaccines for human papilloma virus and methods for using the same |
JP2015514132A (ja) | 2012-04-10 | 2015-05-18 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒト呼吸器合胞体ウイルスコンセンサス抗原、核酸構築物、およびそれらから作製されるワクチン、ならびにその使用方法 |
CN114181961A (zh) * | 2013-03-12 | 2022-03-15 | 宾夕法尼亚大学理事会 | 用于人乳头状瘤病毒的改进疫苗及其使用方法 |
EP3607974A1 (en) | 2013-03-15 | 2020-02-12 | The Trustees of The University of Pennsylvania | Cancer vaccines and methods of treatment using the same |
WO2015103602A1 (en) * | 2014-01-06 | 2015-07-09 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
US11045519B2 (en) | 2017-01-31 | 2021-06-29 | Unm Rainforest Innovations | Arginine-rich polypeptide compositions and methods of using same |
CN111482408A (zh) * | 2020-05-28 | 2020-08-04 | 成都润林医疗器械有限公司 | 具有远程控制系统的清洗机 |
CN114106207B (zh) * | 2022-01-24 | 2022-04-26 | 诺未科技(北京)有限公司 | Ccl5的用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001513986A (ja) * | 1997-08-22 | 2001-09-11 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
JP2001527091A (ja) * | 1997-12-24 | 2001-12-25 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
WO2007121894A2 (en) * | 2006-04-21 | 2007-11-01 | Transgene S.A. | Hpv-18-based papillomavirus vaccine |
WO2008014521A2 (en) * | 2006-07-28 | 2008-01-31 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5077044A (en) * | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
US5338683A (en) * | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US4722848A (en) * | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5174993A (en) * | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US5110587A (en) * | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US4510245A (en) * | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
ZA858044B (en) * | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
US5643579A (en) * | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
US5036006A (en) * | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4945050A (en) * | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4797368A (en) * | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
GB8508845D0 (en) * | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US5223424A (en) * | 1985-09-06 | 1993-06-29 | Prutech Research And Development | Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence |
US4790987A (en) * | 1985-11-15 | 1988-12-13 | Research Corporation | Viral glycoprotein subunit vaccine |
US5310668A (en) * | 1986-06-20 | 1994-05-10 | Merck & Co., Inc. | Varicella-zoster virus as a live recombinant vaccine |
US5242829A (en) * | 1986-09-23 | 1993-09-07 | Therion Biologics Corporation | Recombinant pseudorabies virus |
US5294441A (en) * | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
IL86583A0 (en) * | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
US5387744A (en) * | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
US5112749A (en) * | 1987-10-02 | 1992-05-12 | Praxis Biologics, Inc. | Vaccines for the malaria circumsporozoite protein |
US5225336A (en) * | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
WO1990010693A1 (en) * | 1989-03-08 | 1990-09-20 | Health Research, Inc. | Recombinant poxvirus host selection system |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5591439A (en) * | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
ES2090129T3 (es) * | 1989-03-31 | 1996-10-16 | Univ Washington | Vacunas que contienen microorganismos tipo phop avirulentos. |
EP0431668B1 (en) * | 1989-12-04 | 1995-02-15 | Akzo Nobel N.V. | Recombinant herpesvirus of turkeys and live vector vaccines derived thereof |
US5294548A (en) * | 1990-04-02 | 1994-03-15 | American Biogenetic Sciences, Inc | Recombianant Hepatitis a virus |
AU7906691A (en) * | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
US5462734A (en) * | 1990-11-02 | 1995-10-31 | Wisconsin Alumni Research Foundation | Bovine herpesvirus vaccine and method of using same |
US5240703A (en) * | 1991-03-01 | 1993-08-31 | Syntro Corporation | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof |
US6034298A (en) * | 1991-08-26 | 2000-03-07 | Prodigene, Inc. | Vaccines expressed in plants |
US5955088A (en) * | 1992-02-03 | 1999-09-21 | Cedars-Sinai Medical Center | Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins |
US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
DK0681483T3 (da) | 1993-01-26 | 2005-11-21 | Univ Pennsylvania | Præparater og fremgangsmåder til administration af genetisk materiale |
US5981505A (en) * | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
NZ267838A (en) * | 1993-06-07 | 1997-12-19 | Genentech Inc | Preparation of an hiv gp 120 subunit vaccine involving determining a neutralising epitope in the v2 and/or c4 domains |
US5739118A (en) * | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US6156319A (en) * | 1994-07-25 | 2000-12-05 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex vaccine |
NL9401820A (nl) * | 1994-11-02 | 1996-06-03 | Meyn Maschf | Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte. |
US5962428A (en) * | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US5650309A (en) * | 1995-05-16 | 1997-07-22 | The Regents Of The University Of California | Viral vectors |
US5698202A (en) * | 1995-06-05 | 1997-12-16 | The Wistar Institute Of Anatomy & Biology | Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier |
AUPN443995A0 (en) * | 1995-07-27 | 1995-08-17 | Csl Limited | Papillomavirus polyprotein |
US20050031638A1 (en) * | 1997-12-24 | 2005-02-10 | Smithkline Beecham Biologicals S.A. | Vaccine |
US6589529B1 (en) * | 1998-10-30 | 2003-07-08 | Children's Hospital Medical Center | Rotavirus subunit vaccine |
US7245963B2 (en) * | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US8209006B2 (en) * | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
WO2005033333A2 (en) * | 2003-10-07 | 2005-04-14 | Dako Denmark A/S | Methods and compositions for the diagnosis of cancer |
WO2007119896A1 (en) | 2006-04-19 | 2007-10-25 | Postech Foundation | Compositions comprising hpv polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer |
KR20140137679A (ko) | 2013-05-23 | 2014-12-03 | 삼성전자주식회사 | 카드 소켓 장치 |
-
2009
- 2009-01-30 CA CA2653478A patent/CA2653478A1/en not_active Abandoned
-
2010
- 2010-01-21 US US12/691,588 patent/US8389706B2/en active Active
- 2010-01-22 EP EP10733940.0A patent/EP2393496B1/en active Active
- 2010-01-22 CA CA2749120A patent/CA2749120C/en active Active
- 2010-01-22 CN CN2010800055837A patent/CN102292089A/zh active Pending
- 2010-01-22 WO PCT/US2010/021869 patent/WO2010085697A1/en active Application Filing
- 2010-01-22 PT PT107339400T patent/PT2393496T/pt unknown
- 2010-01-22 AU AU2010206611A patent/AU2010206611B2/en active Active
- 2010-01-22 ES ES10733940.0T patent/ES2592204T3/es active Active
- 2010-01-22 EA EA201170965A patent/EA023892B1/ru not_active IP Right Cessation
- 2010-01-22 CN CN201710280349.9A patent/CN107267530A/zh active Pending
- 2010-01-22 JP JP2011548155A patent/JP5996191B2/ja active Active
- 2010-01-22 MX MX2011007692A patent/MX2011007692A/es active IP Right Grant
- 2010-01-22 KR KR1020117017259A patent/KR101652764B1/ko active IP Right Grant
- 2010-01-22 PL PL10733940T patent/PL2393496T3/pl unknown
-
2015
- 2015-07-31 JP JP2015151495A patent/JP2015192673A/ja not_active Withdrawn
-
2018
- 2018-04-17 HK HK18104980.4A patent/HK1245334A1/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001513986A (ja) * | 1997-08-22 | 2001-09-11 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
JP2001527091A (ja) * | 1997-12-24 | 2001-12-25 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
WO2007121894A2 (en) * | 2006-04-21 | 2007-11-01 | Transgene S.A. | Hpv-18-based papillomavirus vaccine |
WO2008014521A2 (en) * | 2006-07-28 | 2008-01-31 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
Non-Patent Citations (6)
Title |
---|
JPN6014027790; Vaccine vol.26, 2008, pp.5210-5215 * |
JPN6014027792; Vaccine vol.26, 2008, pp.3112-3120 * |
JPN6014027794; JOURNAL OF VIROLOGY vol.81 no.10, 2007, pp.5257-5269 * |
JPN6014027795; The Oncologist vol.10, 2005, pp.528-538 * |
JPN6014027797; Vaccine vol.27, 2008, pp.431-440 * |
JPN6014027799; Vaccine vol.26, 2008, pp.440-448 * |
Also Published As
Publication number | Publication date |
---|---|
CA2749120C (en) | 2019-09-17 |
JP2015192673A (ja) | 2015-11-05 |
MX2011007692A (es) | 2011-08-12 |
EP2393496B1 (en) | 2016-08-03 |
WO2010085697A1 (en) | 2010-07-29 |
AU2010206611A1 (en) | 2011-07-21 |
AU2010206611B2 (en) | 2015-09-17 |
US8389706B2 (en) | 2013-03-05 |
KR20110106901A (ko) | 2011-09-29 |
EA023892B1 (ru) | 2016-07-29 |
EP2393496A4 (en) | 2012-08-29 |
EP2393496A1 (en) | 2011-12-14 |
US20100189730A1 (en) | 2010-07-29 |
KR101652764B1 (ko) | 2016-08-31 |
JP5996191B2 (ja) | 2016-09-21 |
PT2393496T (pt) | 2016-11-10 |
CA2749120A1 (en) | 2010-07-29 |
CN102292089A (zh) | 2011-12-21 |
CA2653478A1 (en) | 2010-07-23 |
HK1245334A1 (zh) | 2018-08-24 |
CN107267530A (zh) | 2017-10-20 |
PL2393496T3 (pl) | 2017-02-28 |
EA201170965A1 (ru) | 2012-01-30 |
ES2592204T3 (es) | 2016-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5996191B2 (ja) | ヒトパピローマウイルスの改良型ワクチンおよびその使用方法 | |
JP2023171837A (ja) | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 | |
US9156890B2 (en) | HCV vaccines and methods for using the same | |
JP2014523436A (ja) | 交差防御性アレナウイルスワクチンおよびそれらの使用方法 | |
US20230277645A1 (en) | Compositions and methods for treating vulvar dysplasia | |
US9050287B2 (en) | Vaccines for human papilloma virus and methods for using the same | |
AU2017265076A1 (en) | Vaccines for Human Papilloma Virus and methods for using the same | |
JP2022554132A (ja) | 再発性呼吸器乳頭腫症のための改善されたワクチンおよびそれを使用するための方法 | |
US20210252134A1 (en) | Vaccines against nipah virus, and methods of using same | |
JP2020039341A (ja) | ヒトパピローマウイルスのワクチンおよびその使用方法 | |
JP6567824B2 (ja) | ヒトパピローマウイルスのワクチンおよびその使用方法 | |
JP6795468B2 (ja) | ヒトパピローマウイルスのワクチンおよびその使用方法 | |
US20220054620A1 (en) | Vaccines against powassan virus, and methods of using same | |
JP5898324B2 (ja) | 改良型hcvワクチンおよびその使用方法 | |
US8921536B2 (en) | HCV vaccines and methods for using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130122 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140701 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140930 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141007 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141028 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150331 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150731 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150916 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20151113 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160824 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5996191 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |